H2020Индивидуална стипендия2021–2023

StemTarget · Development of new therapeutic treatments targeting cancer stem cells.

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2021-04-01 → 2023-03-31
Финансиране от ЕС: 160 932 €
Участници: 1
Схема: MSCA-IF

Линиите свързват координатора с партньорите.

Накратко на български

Канцерните стволови клетки, като тези при остра миелоидна левкемия, се изследват за създаване на нови лекарства. Унищожаването им е важно, защото тези клетки могат да останат спящи, да устоят на химиотерапията и да причинят повторно развитие на рака.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Development of new therapeutic treatments targeting cancer stem cells.

The last decades of research in oncology have demonstrated the existence of a distinct population of tumor cells, named cancer stem cells (CSC) with a central role in tumor spread and drug resistance. Inside the tumor cell population, some cancer cells are called “differentiated cells” and express specific cellular and molecular biomarkers associated with differentiation, while other cells are more immature and present some other distinct features. These cells are also known as “cancer stem cells”. This Skłodowska-Curie Action “Development of new therapeutic treatments targeting cancer stem cells” looks at how trigger this specific population of cancer cells, and how to conceive new anti-cancer drugs. Acute myeloid leukemia (AML) accounts for 30% of leukemia in adults. This blood cancer affects nearly 18,000 new people each year in Europe. It is characterized by an excessive and continuous production of abnormal and immature blood cells within the bone marrow and the blood circulation. Intensive chemotherapies currently in use, however, fail to eradicate leukemic stem cells. These dormant cells do not divide but remain a constant threat for the patients. Indeed, even if they are quiescent cells, they are able to wake up and can be responsible of cancer relapse. They can cause leukemia to progress to a more aggressive or to an anti-cancer treatment-resistant form. Destroying these cancer stem cells is therefore the main objective of this project. The objectives of this project are to (a) collaborate with medical chemists to design new molecules; (b) test all the synthetic compounds in vitro for anti-cancer capacity and toxicity, and (c) develop a platform for drug discovery. A parallel goal of the MSCA Individual Fellowship is also to foster the development of the individual researcher. It would bridge academy with industry and will bring invaluable complementary scientific and soft skills to a researcher with an ideal background in drug development.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Acute myeloid leukemia is characterized by the accumulation of transformed immature myeloid cell in bone marrow. The course of the disease is marked by poor prognosis, frequent relapse, and high disease-related mortality. In spite of improvements in its therapy, above 60% of AML patients will eventually succumb to the disease, a fact stressing the need for new therapeutic approaches for remission induction and prevention of relapse. The difficulty in treating AML is thought to arise from a chemoresistant subpopulation of leukemia stem cells (LSCs) that are capable of maintaining and reinitiating the disease. Increasing evidences suggest that classic neurotransmitter receptors such as dopamine receptors (DRs) and serotonin receptors (HTRs) are involved in cancer genesis and maintenance. Indeed, DRs and HTRs are expressed on the surface of LSCs. By killing differentially LSCs while sparing healthy hematopoietic stem cells (HSCs), DR/HTR antagonists could constitute a new therapeutic target for AML, especially for eradication of LSCs.

Оригинален текст от CORDIS (на английски).

Участници

LEUKOS BIOTECH SL · BarcelonaКоординаторИспания